Novo Nordisk Q3 earnings lifted by demand for new obesity drug -Breaking
[ad_1]
© Reuters. COPENHAGEN (Reuters), Novo Nordisk, a drug developer and investor in pharmaceuticals (NYSE:) announced Wednesday third quarter earnings that were boosted by the strong demand for its latest obesity medication.
Novo recorded a net profit in the third quarter of $12.1 billion Danish crowns ($1.88 million), an 18% increase over last year.
($1 = 6.4217 Danish crowns)
Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.
Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.
[ad_2]
